Milano, Lombardia Jun 25, 2025 (Issuewire.com) - Mestrualia, a pioneering health-tech company, today announced the launch of its AI-driven medical protocol designed to revolutionize the diagnosis and treatment of chronic pelvic pain (CPP), a condition affecting 1 in 5 women globally. By combining early detection with personalized treatment, Mestrualia aims to reduce diagnostic times by up to 80%, slashing both patient suffering and financial burdens.
The journey behind Mestrualia is deeply personal. Founder Franziska Roessler endured years of undiagnosed chronic pelvic pain, navigating a broken system where symptoms were dismissed, misdiagnosed, or inadequately treated. After spending thousands of euros and enduring years of frustration, she realized that millions of women face the same invisible struggle—and few answers.
“I founded Mestrualia because I lived it. The silence, the misdiagnoses, the emotional and financial toll—this is what drives me to build a smarter, faster, and more compassionate solution,” said Roessler. “Our goal is to make sure no woman has to feel ignored or endure seven years of pain without answers.”
A Critical Gap in Women’s Health
Despite its prevalence, over 50% of CPP cases go undiagnosed, with women enduring an average of 7 years on a painful and costly diagnostic journey. Many receive late or incorrect diagnoses, face side effects from generalized treatments, and struggle with limited insurance coverage and a lack of standardized protocols.
The global wellness market, now valued at 5% of the world economy, has seen rapid innovation—yet CPP remains overlooked in clinical practice. Current systems are often obsolete, with low awareness among healthcare providers and few tools designed to handle complex chronic conditions.
This problem is expected to grow: the World Health Orgnization reports that by 2050, more than 2 billion people will be over the age of 60, dramatically increasing demand for chronic health services.
A Smarter, Faster, More Affordable Approach
Mestrualia’s protocol harnesses the power of AI, machine learning, and customized procedures to streamline clinical decision-making. Designed for use by leading healthcare professionals, the system enables:
- Faster and earlier diagnoses using data-driven triage
- Tailored treatment plans that adapt to patient responses
- Lower costs, addressing the €20,000 average spent per patient
- Minimal side effects, through better targeting of interventions
By replacing outdated workflows, Mestrualia introduces a new era of accessible and intelligent gynecological care—rooted in lived experience and technical innovation.
About Mestrualia
Mestrualia is a health technology company focused on transforming the future of women’s health through AI-powered diagnostics and personalized care solutions. Its mission is to close the gender gap in medical research, accelerate time to diagnosis, and improve quality of life for millions—starting with the founder’s own story.
For more information, visit www.mestrualia.com or follow us on LinkedIn and Twitter.
Media Contact
Mestrualia franziska@mestrualia.com http://www.mestrualia.com
